Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

LB54640

Stage Phase 2Stale

Sponsor Rhythm Pharmaceuticals, Inc.

Route oral

Sources

registry, as of 2023-11-02Stale

https://clinicaltrials.gov/study/NCT06046443

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Rhythm Pharmaceuticals, Inc.. Enrollment 28. Conditions Hypothalamic Obesity. The goal of this study was to determine how well LB54640 (also known as bivamelagon) worked and how safe it was in participants with Hypothalamic Obesity (HO). The study evaluated the effect of bivamelagon on safety, weight reduction, hunger, and quality of life in participants 1

ClinicalTrials.gov NCT06046443 protocol and results modules

registry, as of 2023-09-15Stale

https://clinicaltrials.gov/study/NCT06040372

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor LG Chem. Enrollment 112. Conditions Obese; Overweight; Healthy. The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects

ClinicalTrials.gov NCT06040372 protocol and results modules

registry, as of 2023-11-02Stale

https://clinicaltrials.gov/study/NCT06041841

A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity. Overall status UNKNOWN. Phases PHASE2. Lead sponsor LG Chem. Enrollment 4. Conditions POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity. The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity

ClinicalTrials.gov NCT06041841 protocol and results modules

Studies

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Registry NCT06046443

Phase Phase 2

Status Completed

Enrollment 28

Start 2024-07-11

Primary completion 2026-02-09

Study completion 2026-02-09

Catalyst Primary completion. 2026-02-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Bivamelagon Low dose (200 milligrams [mg])

Regimen daily

Weeks 14

Comparator placebo

Population Hypothalamic Obesity

Bivamelagon Middle dose (400 mg)

Dose 400 mg

Regimen daily

Weeks 14

Comparator placebo

Population Hypothalamic Obesity

Bivamelagon High dose (600 mg)

Dose 600 mg

Regimen daily

Weeks 14

Comparator placebo

Population Hypothalamic Obesity

Placebo

Regimen daily

Weeks 14

Population Hypothalamic Obesity

Open-label Bivamelagon

Regimen daily

Weeks 14

Comparator placebo

Population Hypothalamic Obesity

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

Registry NCT06040372

Phase Phase 1

Status Completed

Enrollment 112

Start 2020-03-16

Primary completion 2022-03-30

Study completion 2022-07-30

LB54640

Regimen once daily

Comparator placebo

Population Obese; Overweight; Healthy

Placebo

Regimen once daily

Population Obese; Overweight; Healthy

A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

Registry NCT06041841

Phase Phase 2

Enrollment 4

POMC/PCSK1/LEPR cohort

Regimen once daily

Population POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity